Study | Sample (n) | Dropouts | Study Design | Population | Intervention design | Follow-up period | Outcome Measurement |
---|---|---|---|---|---|---|---|
Huang et al. (2019) [26] | 265 recruited 120 participants (46% female) 40 received PRP, 40 received CS and 40 HA (HA patients not included) | 0 145 did not meet inclusion criteria | Prospective, randomised study | Kellgren/Lawrence grade 1–2 Aged 40–65 Chinese patients recruited from May 2016 | 1 injection per group, received once Anatomically guided injections 4 ml LP-PRP 1 ml corticosteroid | 12 months | WOMAC and VAS scores at 3, 6,9- and 12-months post intervention |
Khan et al. (2018) [29] | 150 patients recruited 101 participants (76.5% female) 52 received PRP, 51 received CS | 49 | Randomised control trial | Kellgren/Lawrence grade 2 and ACR osteoarthritis criteria Aged 40–63 Pakistani patients recruited between July ‘17-July ‘18 | 2 injections per group, given at 0 months and 2 months. Anatomically guided injections 5 ml PRP (LR/LP not specified) 1 mil (40 mg) triamcinolone | 6 months | WOMAC and VAS scores at 2 months, then every 2 weeks until 6 months |
Naderi et al. (2018) [30] | 72 recruited 67 participated (82% female) 33 received PRP, 34 received corticosteroids | 5 | Randomised control trial with Quad ruple block randomisation | Kellgren/Lawrence or ACR grade 2–3 osteoarthritis Aged 30–75 Iranian patients between April ‘16- June ‘17, recruited in a hospital | 3 injections performed once a month for 3 consecutive months in both groups Ultrasound guided injections 5 ml LR-PRP 40 mg triamcinolone | 6 months | VAS and KOOS scores before the onset of treatment, once a month after treatment and 6 months after treatment. |
Freire et al. (2018) [28] | 50 patients (25 PRP, 25 corticosteroids) (84% female) Double-blinded block randomisation | 0 | Randomised, controlled, longitudinal, double blind, comparative, descriptive study | Kellgren/Lawrence 2–4 Aged 30–90 Brazilian patients, recruited in a medical centre | 1 injection performed once in each group Anatomically guided injections 5 ml LP- PRP 2.5 ml triamcinolone | 6 months | KSS, WOMAC, Kellgren-Lawrence scores evaluated before treatment, at 1 months and 6 months post-intervention |
Camurcu et al. (2018) [31] | 132 patients recruited (83% female) 37 PRP, 40 PRP+ steroid, 38 steroid | 17 | Prospective longitudinal study | Kellgren-Lawrence grade 2–3 Aged 40–80 Turkish patients recruited in 2016 | 1 injection of PRP only, PRP + steroid, or steroid only Anatomically guided injection 3 ml LR-PRP 1 ml methylprednisolone | 12 months (for 115 patients) | VAS and WOMAC at 1,3, 6- and 12-months post-intervention |
Phul et al. (2018) [27] | 80 patients recruited 40 in each group: PRP or corticosteroid (67.5% female) | 0 | Randomised control trial | Kellgren/Lawrence grade 2–4 Aged 40–75 Pakistani patients recruited between Feb- August 2015 | 1 injection in both groups Anatomically guided injection for PRP; fluoroscopically guided corticosteroid injection 4–6 microml LR-PRP 40 ml triamcinolone | 3 months | VAS at baseline and 3 months post-intervention |
Uslu et al. (2017) [20] | 57 patients recruited 50 participants (92% female) 17 received CS, 19 single PRP, 14 triple PRP injection | 7 | Prospective, randomised, single-blind (physician blind) | Kellgren/Lawrence grade 3 Aged 50–75 Turkish patients between June ‘15- March ‘16, hospital setting | 3 groups receiving either 1 PRP injection, 3 PRP injections (given 1 week apart) or 1 steroid injection Anatomically guided injections LR-PRP, dose not specified Corticosteroid suspension equivalent to 5 mg betamethasone | 6 months | VAS, WOMAC and HAD scale (an assessment of anxiety and depression) with follow up at baseline, 2 and 6 months post-intervention |
Jubert et al. (2017) [22] | 65 patients included (72% female) 35 PRP, 30 corticosteroid | 0 | Prospective randomised, double-blind, parallel controlled study | Kellgren/Lawrence grade 3–4 Aged 40–80 Patients between Aug ‘13- July ‘14 | 1 injection per group given once Anatomically guided injections 4 ml LP-PRP 2 ml betamethasone | 6 months | VAS, KOOS and SF36 scores at 1, 3- and 6-months post-intervention |